Successful Strategies for the Discovery of Antiviral Drugs
The antiviral therapeutic area continues to rapidly generate meaningful new chemical entities; for example, for HIV alone more than 25 drugs have been approved, and in the next few years many individual drugs and single tablet regimens will be approved for the treatment of hepatitis C virus infection. The increasing success in the antiviral area could be due to targeting drugs at "non-self" genomes and to the patient population that is tolerant of manageable side effects and adaptable to inconvenient dosing.
Aimed at medicinal chemists and emerging drug discovery scientists, the book is organized according to the various strategies deployed for the discovery and optimization of initial lead compounds. This book focuses on capturing tactical aspects of problem solving in antiviral drug design, an approach that holds special appeal for those engaged in antiviral drug development, but also appeals to the broader medicinal chemistry community based on its focus on tactical aspects of drug design.
Successful Strategies for the Discovery of Antiviral Drugs, The Royal Society of Chemistry, 2013.
Download citation file:
Digital access
Print format
Table of contents
-
CHAPTER 1: Discovery and Clinical Validation of HCV Inhibitors Targeting the NS5A Proteinp3-28ByMakonen Belema;Makonen BelemaDepartment of Medicinal Chemistry andSearch for other works by this author on:Nicholas A. Meanwell;Nicholas A. MeanwellDepartment of Medicinal Chemistry andSearch for other works by this author on:John A. Bender;John A. BenderDepartment of Medicinal Chemistry andSearch for other works by this author on:Omar D. Lopez;Omar D. LopezDepartment of Medicinal Chemistry andSearch for other works by this author on:Piyasena Hewawasam;Piyasena HewawasamDepartment of Medicinal Chemistry andSearch for other works by this author on:David R. LangleyDavid R. LangleyDepartment of Computer‐Assisted Drug DesignBristol‐Myers Squibb Research and Development, 5 Research Parkway, Wallingford, CT 06492USA[email protected]Search for other works by this author on:
-
CHAPTER 2: Respiratory Syncytial Virus Fusion Inhibitorsp29-62ByRichard MackmanRichard MackmanSearch for other works by this author on:
-
CHAPTER 3: Phenotypic Screening to Discover Inhibitors of Dengue Virusp63-80ByQing‐Yin Wang;Qing‐Yin WangNovartis Institute for Tropical Diseases10 Biopolis Road, 05‐01 ChromosSingapore 138670[email protected]Search for other works by this author on:Bin Zou;Bin ZouNovartis Institute for Tropical Diseases10 Biopolis Road, 05‐01 ChromosSingapore 138670[email protected]Search for other works by this author on:Simon J. Teague;Simon J. TeagueNovartis Institute for Tropical Diseases10 Biopolis Road, 05‐01 ChromosSingapore 138670[email protected]Search for other works by this author on:Pei‐Yong ShiPei‐Yong ShiNovartis Institute for Tropical Diseases10 Biopolis Road, 05‐01 ChromosSingapore 138670[email protected]Search for other works by this author on:
-
CHAPTER 4: Discovery and Development of Antiviral Drugs for Treatment of Pathogenic Human Orthopoxvirus Infectionsp81-110ByRobert JordanRobert JordanSearch for other works by this author on:
-
CHAPTER 5: HCV Replication Inhibitors That Interact with NS4Bp111-145ByChristopher D. Roberts;Christopher D. RobertsGlaxoSmithKline Research & DevelopmentInfectious Diseases Therapeutic Area Unit, 5 Moore Drive, Research Triangle Park, NC 27709USA[email protected]Search for other works by this author on:Andrew J. PeatAndrew J. PeatGlaxoSmithKline Research & DevelopmentInfectious Diseases Therapeutic Area Unit, 5 Moore Drive, Research Triangle Park, NC 27709USA[email protected]Search for other works by this author on:
-
CHAPTER 6: HIV Integrase Inhibitorsp149-188ByBrian A. Johns;Brian A. JohnsGlaxoSmithKline Research & DevelopmentInfectious Diseases Therapeutic Area Unit, 5 Moore Drive, Research Triangle Park, NC 27709USASearch for other works by this author on:Takashi Kawasuji;Takashi KawasujiShionogi Pharmaceutical Research CenterChemistry of Infectious Diseases, 3‐1‐1, Futaba‐cho, Toyonaka‐shi, Osaka 561‐0825Japan[email protected]Search for other works by this author on:Emile J. VelthuisenEmile J. VelthuisenGlaxoSmithKline Research & DevelopmentInfectious Diseases Therapeutic Area Unit, 5 Moore Drive, Research Triangle Park, NC 27709USASearch for other works by this author on:
-
CHAPTER 7: HCV NS3/4a Protease Inhibitors: Simeprevir (TMC‐435350), Vaniprevir (MK‐7009) and MK‐5172p189-247ByJohn A. McCauley;John A. McCauleyDepartment of Medicinal ChemistryMerck Research Laboratories, West Point, PA 19486USA[email protected]Search for other works by this author on:Michael T. Rudd;Michael T. RuddDepartment of Medicinal ChemistryMerck Research Laboratories, West Point, PA 19486USA[email protected]Search for other works by this author on:Nigel J. LivertonNigel J. LivertonDepartment of Medicinal ChemistryMerck Research Laboratories, West Point, PA 19486USA[email protected]Search for other works by this author on:
-
CHAPTER 8: Design and Development of NS5B Polymerase Non‐nucleoside Inhibitors for the Treatment of Hepatitis C Virus Infectionp248-294ByPierre L. BeaulieuPierre L. BeaulieuBoehringer Ingelheim (Canada) Ltd.2100 Cunard Street, Laval, QuébecCanada, H7S 2G5resgeneral.lav@boehringer‐ingelheim.comSearch for other works by this author on:
-
CHAPTER 9: Virus‐coded Ion Channels as Antiviral Targetsp295-362ByStephen GriffinStephen GriffinLeeds Institute of Molecular Medicine, Faculty of Medicine and HealthUniversity of Leeds, Wellcome Trust Brenner Building, St. James’ University Hospital, Beckett StreetLeeds LS9 7TF, UK[email protected]Search for other works by this author on:
-
CHAPTER 10: TLR‐7 Agonists for the Treatment of Viral Hepatitisp365-383ByRandall L. HalcombRandall L. HalcombGilead Sciences Inc.Department of Medicinal Chemistry, 333 Lakeside Drive, Foster City, CA 94404USA[email protected]Search for other works by this author on:
-
CHAPTER 11: Optimization of Cyclophilin Inhibitors for Use in Antiviral Therapyp384-418ByAndrew ScribnerAndrew ScribnerSearch for other works by this author on:
-
CHAPTER 12: Prodrugs in the Treatment of Viral Diseasesp421-450ByMichael J. SofiaMichael J. SofiaOncore Biopharma and Institute for Hepatitis and Virus ResearchThe Pennsylvania Commonwealth Institute, 3805 Old Easton Road, Doylestown, PA 18902USA[email protected]Search for other works by this author on:
-
CHAPTER 13: Cobicistat and Ritonavir as Pharmacoenhancers for Antiviral Drugsp451-481ByManoj C. DesaiManoj C. DesaiSearch for other works by this author on:
-
CHAPTER 14: Clinical Benefits of Single‐tablet Regimensp482-508ByBill GuyerBill GuyerSearch for other works by this author on:
Spotlight
Advertisement
Advertisement